Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Preoperative 5-Fu based chemoradiation has become standard treatment for stage 2/3
rectal cancer. However whether these patients, especially T3N0-1M0 patients, really need
radiation for local control after total mesentery excision being applied in routine practice
is still unknown. And whether new drugs adding in can achieve better local and distant
control is worth investigating.
PURPOSE: This randomized phase II trial is studying 5Fu based radiation therapy or FOLFOX
based radiation or FOLFOX alone, comparing them to see how well they work when given before
surgery in treating patients with intermediate risk resectable rectal cancer. It is not yet
known whether 5-Fu based or FOLFOX based radiation therapy or even FOLFOX alone is more
effective in treating rectal cancer.